?????? ????????????? ??????????????????? ???????????????????????PDUFA dates and FDA Panel Evaluate dates are crucial catalysts mainly because they are ‘make or break occasions’ for biotech shares.Negotiations above the 2022 reauthorization advise that field priorities contain enhanced software of serious-environment evidence, regulatory certain